Frontline antibody-drug conjugates boost progression-free survival in metastatic triple-negative breast cancer, showing early overall survival gains and expanding options.
Natalie Berger, MD
Natalie Berger, MD is an assistant professor of Medicine at CUMC, Division of Hematology and Medical Oncology and associate director of Breast Medical Oncology at NYP-Hudson Valley Hospital with a focus in breast cancer.
Articles by Natalie Berger, MD
New HER2+ breast cancer trials refine chemo and antibody use—cutting toxicity with de‑escalation, while escalating high‑risk patients with T‑DXd.
Natalie Berger, MD, weighed the biggest hurdles she witnesses in HPV vaccination and screening adherences.
See how breast cancer endocrine and targeted drugs inform endometrial and ovarian care—tamoxifen, CDK4/6 combos, and T-DXd.
Latest Updated Articles
The Intersection of Breast and Gyn Cancer TreatmentsMarch 10th 2026
